BRAF and fibrosarcoma: Sorafenib is a multikinase inhibitor that inhibits mitogen-activated protein kinase (MAPK) pathway kinases rapidly accelerated fibrosarcoma (Raf)-1, wild-type B-Raf, and mutant B-Raf.